Kura Oncology is discontinuing development of one of its three clinical-stage cancer drug candidates amid pandemic-related impacts to its clinical trial plans.
The decision to end work on the drug, KO-947, comes after San Diego-based Kura (NASDAQ: KURA) was successful in lifting a partial clinical hold placed on a Phase 1 trial of the drug earlier this year by the FDA following a serious side effect experienced by one patient in the study.
The company had recently landed on a recommended Phase 2 dose of KO-947, and was preparing to test it in patients with head and neck squamous cell… Read more »
UNDERWRITERS AND PARTNERS
